.png)
Illustration of the NIR-PICT³ treatment in action: (1) Antibodies (mAb) carrying a light-activated dye (IR700) and tiny iron particles (green) attach to cancer cells in a tumor. The dye’s glow and the iron particles let researchers track the drug using fluorescence imaging and MRI. When near-infrared (NIR) light shines on the tumor, (2) the targeted cells burst, (3) the particles heat up, and (4) they trigger damaging chemical reactions. (5) The light also opens up the tumor’s blood vessels, letting more particles in. (6) The heat then destroys nearby cancer cells that the drug could not target.
Image Credit: Adapted from Matsuoka et al., Journal of Nanobiotechnology (2026)
(CC BY-NC-ND 4.0)
Scientific Frontline: Extended "At a Glance" Summary: Iron Oxide Nanoparticle-Enhanced Near-Infrared Photoimmunotherapy (NIR-PICT3)
The Core Concept: Researchers at Nagoya University developed an enhanced light-based cancer therapy, termed near-infrared photoimmuno-chemodynamic thermal targeting therapy (NIR-PICT3), by attaching 20 nm iron oxide nanoparticles to dye-carrying, cancer-targeting antibodies. In mouse models, this platform enables magnetic resonance imaging (MRI) tumor tracking and destroys both targeted cancer cells and neighboring untargeted tumor cells that typically evade standard treatment.
Key Distinction/Mechanism: Unlike conventional near-infrared photoimmunotherapy (NIR-PIT), which only ruptures cells expressing the target protein epidermal growth factor receptor (EGFR) and suffers from limited surface-level dye visibility, NIR-PICT3 accumulates in tumors after bloodstream injection to provide clear MRI contrast while executing a triple-action assault under near-infrared (NIR) light. Irradiation causes targeted cells to burst, heats the iron oxide particles to kill adjacent antigen-negative cells via a newly identified "photothermal bystander effect," and triggers damaging chemical reactions inside cancer cells. Furthermore, the initial light exposure dilates tumor blood vessels, allowing subsequent nanoparticle accumulation and amplifying thermal destruction with each repeated round of therapy.
Origin/History: Conventional NIR-PIT received conditional approval in Japan in 2020 for treating recurrent head and neck cancer and has since advanced to late-stage clinical trials in the United States. Prior attempts to combine antibodies with nanoparticles failed to achieve effective tumor accumulation because larger constructs were sequestered by the liver or spleen, though larger iron oxide particles have already gained clinical approval as MRI contrast agents.




.png)













